Psoriatic Arthritis

Psoriatic Arthritis Impact of Disease test can be administered via a touch screen.

Study evaluates whether etanercept monotherapy treats psoriatic arthritis as effectively as the combination of etanercept and methotrexate.

Certolizumab pegol is a safe alternative tumor necrosis factor-a inhibitor with some benefits for psoriatic arthritis patients.

Study evaluates whether smoking cigarettes worsens clinical damage in PsA patients as it does in rheumatoid arthritis and ankylosing spondylitis.

Ixekizumab found safe and effective for short term treatment of moderate-to-severe plaque-type psoriasis.

Duration of psoriasis at baseline impacts the odds of developing erosion in psoriatic arthritis.

Tofacitinib may offer an effective oral option for patients with psoriatic arthritis.

Inflectra biosimilar treats conditions such as Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.

Study finds 15.5% of all psoriasis patients had undiagnosed psoriatic arthritis.

Tofacitinib is an oral Janus kinase inhibitor that improves the signs and symptoms of psoriatic arthritis.

The oral Janus kinase inhibitor tofacitinib treats adults with active psoriatic arthritis (PsA).

Biosimilar infliximab-dyyb (Inflectra) treats a variety of autoimmune diseases.

Biosimilar infliximab-dyyb (Inflectra) treats a variety of autoimmune diseases, including Crohn’s disease, rheumatoid arthritis, and psoriatic arthritis.

Ixekizumab (Taltz) approved for moderate-to-severe plaque psoriasis in adults.

Etanercept shows sustained efficacy treating the symptoms of 3 juvenile idiopathic arthritis categories.

Toll-like receptor 4 behave differently on psoriasis skin compared with uninvolved skin.

There are several ongoing global phase 3 clinical trials for biosimilar adalimumab, which treats conditions such as rheumatoid arthritis, psoriatic arthritis, and Crohn's Disease.

Psoriatic arthritis patients who achieve persistent minimal disease activity more likely to experience long-term improvement with golimumab.

Psoriatic arthritis patients are more likely to develop conditions such as hypertension, diabetes, obesity, and dyslipidemia.

Sernivo Spray treats mild-to-moderate plaque psoriasis in patients 18 years of age and up.

Higher risk of serious infection found with adalimumab and infliximab compared with nonmethotrexate and nonbiologic therapies.

Brodalumab is monoclonal antibody that targets the IL-17 receptor.

Cutaneous psoriasis used to describe an individual who suffered from the disease for at least a decade.

Patients with inflammatory rheumatic diseases may not need more frequent vaccinations.

Cosentyx was previously approved for the treatment of moderate-to-severe plaque psoriasis.